Myriad Loses Bid to Block Ambry Cancer Tests in Patent Row - McDermott Will & Emery

Myriad Loses Bid to Block Ambry Cancer Tests in Patent Row

Overview


William Gaede and Eric Hagen were co-counsel successfully representing life sciences company Ambry Genetics in Utah federal court litigation. The court halted a competitor’s attempt to block sales of Ambry cancer-testing products that it claimed infringe several of its patents, ruling that Ambry had raised sufficient questions about the patents’ validity.